Advanced Clinical Selects TRI RBM Platform

Article

Applied Clinical Trials

TRI will be providing the OPRA platform for all of Advanced’s studies whose sponsors have requested a risk-based approach to monitoring.

Advanced Clinical, a Chicago-based CRO, has selected Triumph Research Intelligence (TRI) OPRA RBM technology platform and accompanying RBM service offerings. TRI will be providing the OPRA platform for all of Advanced’s studies whose sponsors have requested a risk-based approach to monitoring. TRI will be supporting Advanced in optimizing their monitoring processes, implementing change management, and supporting study specific key risk indicator design.

Read the full release.

 

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.